ES2191329T3 - Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares. - Google Patents

Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.

Info

Publication number
ES2191329T3
ES2191329T3 ES98943128T ES98943128T ES2191329T3 ES 2191329 T3 ES2191329 T3 ES 2191329T3 ES 98943128 T ES98943128 T ES 98943128T ES 98943128 T ES98943128 T ES 98943128T ES 2191329 T3 ES2191329 T3 ES 2191329T3
Authority
ES
Spain
Prior art keywords
duration
treatment
improvement
disorders
muscle function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98943128T
Other languages
English (en)
Inventor
Ake Lignell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOPROCESS SWEDEN AB
Original Assignee
BIOPROCESS SWEDEN AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BIOPROCESS SWEDEN AB filed Critical BIOPROCESS SWEDEN AB
Application granted granted Critical
Publication of ES2191329T3 publication Critical patent/ES2191329T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Uso de al menos un tipo de xantófilos en la preparación de un medicamento para la mejora profilática y/o terapéutica de la duración de la función del músculo en mamíferos y/o el tratamiento de los desórdenes o enfermedades del músculo en mamíferos.
ES98943128T 1997-09-04 1998-08-26 Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares. Expired - Lifetime ES2191329T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Publications (1)

Publication Number Publication Date
ES2191329T3 true ES2191329T3 (es) 2003-09-01

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98943128T Expired - Lifetime ES2191329T3 (es) 1997-09-04 1998-08-26 Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.

Country Status (13)

Country Link
US (1) US6245818B1 (es)
EP (1) EP1011653B1 (es)
JP (1) JP3660244B2 (es)
AT (1) ATE230985T1 (es)
AU (1) AU727349B2 (es)
CA (1) CA2299366C (es)
DE (1) DE69810784T2 (es)
DK (1) DK1011653T3 (es)
ES (1) ES2191329T3 (es)
NO (1) NO20001087D0 (es)
PL (1) PL338982A1 (es)
SE (1) SE512531C2 (es)
WO (1) WO1999011251A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
CN1708480B (zh) 2002-07-29 2010-12-15 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
WO2004021798A1 (es) * 2002-09-03 2004-03-18 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
ES2587652T3 (es) * 2004-02-04 2016-10-26 Fuji Chemical Industry Co., Ltd. Astaxantina para mejorar la atrofia muscular
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2006039685A2 (en) 2004-10-01 2006-04-13 Hawaii Biotech, Inc. Methods for synthesis of chiral intermediates of carotenoids, carotenoid analogs, and carotenoid derivatives
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) * 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) * 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) * 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
WO1996023489A2 (de) * 1995-02-03 1996-08-08 Basf Aktiengesellschaft Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
DK1011653T3 (da) 2003-05-26
SE9703191L (sv) 1999-03-05
AU727349B2 (en) 2000-12-14
ATE230985T1 (de) 2003-02-15
NO20001087L (no) 2000-03-02
DE69810784D1 (de) 2003-02-20
CA2299366A1 (en) 1999-03-11
US6245818B1 (en) 2001-06-12
DE69810784T2 (de) 2003-11-13
CA2299366C (en) 2008-04-22
SE9703191D0 (sv) 1997-09-04
JP2001514215A (ja) 2001-09-11
AU9098998A (en) 1999-03-22
EP1011653A1 (en) 2000-06-28
EP1011653B1 (en) 2003-01-15
JP3660244B2 (ja) 2005-06-15
NO20001087D0 (no) 2000-03-02
SE512531C2 (sv) 2000-03-27
WO1999011251A1 (en) 1999-03-11
PL338982A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
PT97552A (pt) Processo para a preparacao de formas de dosagem para administracao de farmacos para o tratamento da doenca de parkison
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
DK0991479T3 (da) Pakningsenhed til indgivelse til lugteområdet
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BR9909192A (pt) Preparações galênicas de meloxicam para administração oral
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
BR9811086A (pt) Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
MX9400287A (es) Procedimiento para la preparacion de un medicamento util para el tratamiento de la enfermedad de parkinson
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
AU3401093A (en) Therapeutic agent for threatened abortion
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.